anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, pharmaceutical industry. SUBSTANCE: invention relates to medicinal agents comprising derivatives of 10-carboxymethyl-9-acridanone. Invention relates to the proposed solid medicinal agent presenting tablet comprising core based on 2-(9-oxo-9,10- dihydroacridin-10-yl)-acetate sodium as active substance, binding additions, filling agents and acid-resistant protective cover. Tablet core is formed from micronized granules or pellets of size 30 mcm, not above, with residual moisture 3-4% that are obtained preliminary by spraying drying method of mixture of active substance, polysaccharide, in part, polyglucine and purified water. Tablet core comprises 0.125-0.215 g of active substance.. In the process of preparing core from micronized pellets polyvinyl-pyrrolidone, sodium chloride and talc are used as binding and filling agents. In the process of preparing core based on micronized granules polyvinylpyrrolidone, lactose, starch and calcium stearate are used as binding and filling agents. Protective acid-resistant cover is prepared on the basis of polymethylacrylate and accessory substances. Invention provides stability of the solid medicinal form. EFFECT: improved properties of agent. 7 cl, 2 tbl, 6 ex
PURPOSE: A conjugate containing carboxylic acid and non-antigenic hydrophilic biocompatible polymer is provided to minimize physiological activity reduction of erythropoietin and to enhance drug efficiency in the human body. CONSTITUTION: A conjugated of biocompatible polymer and EPO(erythropoietin) is prepared by binding biocompatible polymer with C-terminal of EPO by carboxyl group. The EPO is derived from human. The biocompatible polymer is polyethylene glycol(PEG). The molecular weight of PEG is 1,000-100,000. The biocompatible polymer is bound to the carboxyl group of EPO in mole ratio of 1:1. A pharmaceutical composition for treating or preventing anemia and hematopoiesis-relating diseases contains the conjugate of biocompatible polymer and EPO and pharmaceutically acceptable carrier.
Idiopathic pulmonary fibrosis (IPF) is a chronic lethal disease in the absence of demonstrated efficacy for preventing progression. Although macrophage-mediated alveolitis is determined to participate in myofibrotic transition during disease development, the paradigm of continuous macrophage polarization is still under-explored due to lack of proper animal models. Here, by integrating 2.5 U/kg intratracheal Bleomycin administration and 10 Gy thorax irradiation at day 7, we generated a murine model with continuous alveolitis-mediated fibrosis, which mimics most of the clinical features of our involved IPF patients. In combination with data from scRNA-seq of patients and a murine IPF model, a decisive role of CCL2/CCR2 axis in driving M1 macrophage polarization was revealed, and M1 macrophage was further confirmed to boost alveolitis in leading myofibroblast activation. Multiple sticky-end tetrahedral framework nucleic acids conjunct with quadruple ccr2-siRNA (FNA-siCCR2) was synthesized in targeting M1 macrophages. FNA-siCCR2 successfully blocked macrophage accumulation in pulmonary parenchyma of the IPF murine model, thus preventing myofibroblast activation and leading to the disease remitting. Overall, our studies lay the groundwork to develop a novel IPF murine model, reveal M1 macrophages as potential therapeutic targets, and establish new treatment strategy by using FNA-siCCR2, which are highly relevant to clinical scenarios and translational research in the field of IPF.
PCT No. PCT/JP95/01270 Sec. 371 Date Feb. 26, 1996 Sec. 102(e) Date Feb. 26, 1996 PCT Filed Jun. 26, 1995 PCT Pub. No. WO96/00240 PCT Pub. Date Jan. 4, 1996A protein is provided derived from human fibroblast having an N-terminal amino acid sequence represented by SEQ ID NOS: 1 and 2, having a molecular weight of approximately 15kD under reducing and non-reducing conditions by (dosium dodecyl sulfate-polyacrylamide gel electrophoresis), and having an activity to stimulate growth of osteoblast. The protein is produced by gene engineering procedures, contains the amino acid sequence represented by SEQ ID NO: 9 and has osteoblast growth activity. Also provided is a method for preparing the protein by culturing human fibroblast and treating the conditioned medium for purification. The protein is utilized for the treatment of diseases characterized by decreased bone mass such as osteoporosis or is utilized as an antigen for immunological diagnosis of diseases.
Background: Small bowel bleeding (SB) comprises 5%-10% of gastrointestinal (GI) bleeding cases. This article describes the staged retrograde intraoperative enteroscopy (SRIE) surgical technique for the etiological diagnosis and treatment of small bowel bleeding. Methods: SRIE was performed on patients with persistent SB at a quaternary university hospital in Brazil from 2020 to 2023. The technique is described in 5 steps, alongside visual aids, including images and a depicting a portion of the procedure. Patients presenting with confirmed coagulopathies, pregnancy, or unwillingness for surgery were excluded. Surgical procedures were performed after informed consent. Case Series: Four participants were submitted to SRIE, including 2 females (64 and 83 years old), and 2 males (46 and 57 years old). Three out of four (75%) of the patients received a confirmed diagnosis of GI bleeding, attributed to angioectasia, acquired von Willebrand disease, and vitamin K deficiency. SRIE was conducted via enterotomy, involving a subsequent insufflation-inspection-deflation of 10 to 10 cm segments of the small bowel (Steps 1 to 5). The procedure was successfully executed in all four patients without complications, allowing confirmation of the etiological diagnosis of SB or exclusion of anatomical causes of hemorrhage. Conclusions: SRIE is a valuable but invasive tool for assessing SB hemorrhage when conventional imaging falls short. When performed systematically and standardized, it allows accurate visualization of SB using a standard endoscope.
The occurrence of gastrointestinal dysfunction is widely recognized as a prevalent complication in patients with sepsis. To investigate clinical effect of Sini Decoction at acupoint on gastrointestinal dysfunction in sepsis patients. Seventy-five patients with gastrointestinal dysfunction caused by sepsis were randomly divided into 2 groups. Treatment group received routine Western medicine treatment combined with Sini Decoction at acupoint, while control group treated with talcum powder at acupoint. Treatments in both groups lasted 7 days. Changes in the acute physiology and chronic health evaluation II score, sequential organ failure assessment score, mechanical ventilation duration, the length of Intensive Care Unit (ICU) stay, enteral nutrition tolerance scores, abdominal circumference, gastric residual volume, bowel sounds, and serum index were observed. After treatment, the enteral nutrition tolerance score, abdominal circumference, gastric residual volume, and levels of lactate and interleukin-6 were significantly lower in the treatment group compared to the control group. Bowel sounds were more active and motilin levels were higher in the treatment group. Additionally, the length of ICU stay was significantly shorter in the treatment group than in the control group. Our findings demonstrated that the application of Sini Decoction at acupoints in sepsis patients with gastrointestinal dysfunction can effectively enhance gastrointestinal function, leading to a reduction in ICU stay duration and an improvement in patients' prognosis.
Participants will take SAS0421a and SAS0421b for 3 days. Half doses will be given on the first night.
An example system may comprise a control module associated with a computing device. After receiving input from a user device the control module may provide the input to a filter AI model. When the filter AI model returns an indication that the input is legitimate, the control module may create a prompt and provide it to an AI model, which determines at least one configuration a response to the prompt should be configured and return at least one short code associated with the at least one determined configuration. The control module may provide the prompt to at least one tuned AI model associated with the associated configuration(s). The control module may receive a response from the AI model(s). Before the control module may transmit the response to the user device, a second filter AI model may return an indication that the response does not violate established standards of quality.
Living virus culture vaccine against canine distemper comprises an attenuated strain EPM No. 10-76 obtd. from the wield virus. It is isolated from a mink having distemper by multiple passage of the virus on (1) dog kidney cell culture, (2) continuous cell culture of the kidneys of the human embryo Rh and (3) mixed culture of dog kidney cells and Japanese quail embryo cells, adapted to the Japanese quail embryo cell culture and grown on this cell culture. The vaccine is harmless, it does not produce toxic effects on admin. and it is obtd. economically. The vaccine has high antigenic activity, it produces effective and persistent immunity in treated animals and vaccination in the epizootic foci of canine may be distemper rapidly eradicates infection. The vaccine may be given parenterally or in aerosol form, and since it is highly active, the amts. required for 1-500 doses can easily be filled into vials.
The invention relates to a traditional Chinese medicine composition for treating chronic pharyngitis. The invention is characterized in that the traditional Chinese medicine composition is composed of the following components in parts by weight: 5-15 parts of balloonflower, 20-30 parts of honey, 10-30 parts of lily root, 5-10 parts of climbing fern spore, 5-10 parts of ginger, 5-10 parts of immature bitter orange, 10-20 parts of trichosanthes kirilowii Maxim peel, 10-20 parts of taraxacum, 5-10 parts of belamcanda rhizome, 5-10 parts of radix bupleuri stir-fried with vinegar, 5-15 parts of semen celosiae and 5-10 parts of coptis. The traditional Chinese medicine composition for treating chronic pharyngitis is prepared according to the traditional Chinese medicine theory. The traditional Chinese medicines are combined to have the synergetic effect of treating chronic pharyngitis. The traditional Chinese medicine preparation made from the traditional Chinese composition has the advantages of small toxic and side effects and low cost. The traditional Chinese medicine composition is subjected to superfine grinding, and thus, the effective component utilization ratio is high. The traditional Chinese medicine composition is immersed and flushed with clear water to remove pollutants attached to the surface of the medicinal materials.
The invention discloses a litchi beverage having the effect of treating joint soreness and relates to the field of functional beverages. The litchi beverage is prepared from radix stephaniae tetrandrae, dried ginger, roots of cornus macrophylla wall, beet roots, nymphoides, maytenus confertiflorus, daphne flowers, corn stigmas, themeda roots, pittosporum roots, semen brassicae, dried rehmannia roots, hypericum attenuatum, flastem milkvetch seeds, rhizome phragmitis, loofah sponge and litchi powder. According to the litchi beverage, roots of cornus macrophylla wall, beet roots, daphne flowers, themeda roots and pittosporum roots serve as effective ingredients for treating joint soreness, and are in compatibility with other ingredients to achieve the effects of smoothing channels, invigorating the circulation of blood, dispelling wind, relieving soreness and the like. Conditioning is carried out according to the fundamental etiological factors, determined through the traditional Chinese medicine, of joint soreness, treatment rules are clear, medicine conditioning the spleen, the liver, the kidneys, the stomach and the like is used for reasonable compatibility, and the effect of treating joint soreness is achieved. The traditional Chinese medicine is safe in clinical application and does not stimulate the viscera when taken. Litchi powder is used for flavoring, and the acceptance of the beverage is improved; meanwhile, litchi also has the effects of tonifying the heart, soothing the nerves, warming the middle warmer and relieving soreness.
BACKGROUND: Recent studies have associated immune abnormalities with dementia. IL-6 is a crucial cytokine in inflammatory responses, and recent evidence has linked elevated IL-6 levels to changes in brain structure and cognitive decline. However, the connection between IL-6 levels, cognition, brain volumes, and dementia risk requires exploration in large prospective cohorts.
METHODS: This study utilized a longitudinal cohort from the UK Biobank to analyze the correlation between IL-6 expression levels, cognitive performance, and cortical and subcortical brain volumes through linear regression. Additionally, we assessed the association between IL-6 levels and long-term dementia risk using Cox regression analysis. We also used one-sample Mendelian randomization to analyze the impact of genetic predisposition of dementia on elevated IL-6 levels.
RESULTS: A total of 50,864 participants were included in this study, with 1,391 new cases of all-cause dementia identified. Higher plasma IL-6 levels are associated with cortical and subcortical atrophy in regions such as the fusiform, thalamus proper, hippocampus, and larger ventricle volumes. IL-6 levels are negatively associated with cognitive performance in pair matching, numeric memory, prospective memory, and reaction time tests. Furthermore, elevated IL-6 levels are linked to a 23-35 % increased risk of all-cause dementia over an average follow-up period of 13.2 years. The one-sample Mendelian randomization analysis did not show associations between the genetic predisposition of dementia and elevated IL-6 levels.
CONCLUSIONS: Increased IL-6 levels are associated with worse cognition, brain atrophy, and a heightened risk of all-cause dementia. Our study highlights the need to focus on the role of peripheral IL-6 levels in managing brain health and dementia risk.
The invention belongs to the field of immunology, and relates to a single domain antibody for resisting CD25 and application thereof. The single domain antibody is composed of a heavy chain, wherein the heavy chain comprises a heavy chain CDR1 shown by any one of SEQ ID NO. 48-SEQ ID NO. 57, a heavy chain CDR2 shown by any one of SEQ ID NO. 58-SEQ ID NO. 67 and a heavy chain CDR3 shown by any one of SEQ ID NO. 68-SEQ ID NO. 78. Compared with the prior art, the invention has the beneficial effects that: the invention screens out the single-domain antibody specific to the CD25 by using a biological genetic engineering technology, has better antibody affinity, can block specific cells from releasing cytokines, has good binding activity through prokaryotic expression and eukaryotic expression, and has certain druggability.
Estradiol valerate injection, USP is indicated in the:

  1. Treatment of moderate to severe vasomotor symptoms associated with the menopause.
  2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.
  3. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure.
  4. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).
ETHNOPHARMACOLOGICAL RELEVANCE: Within Anemarrhena asphodeloides Bunge (AAB), the pivotal bioactive constituents are identified as Anemarrhena asphodeloides Bunge total saponins (ABS). In traditional pharmacology, ABS has exhibited notable anti-inflammatory, hypoglycemic, and cardioprotective properties. Despite these observed effects, the specific protective mechanisms of ABS against metabolic diseases and improving the endocrine system remain largely uncharted.
AIM TO STUDY: This work intends to shed light on the effects and intrinsic mechanisms of ABS on metabolic diseases.
MATERIALS AND METHODS: The characterization of ABS components was achieved through High-Performance Liquid Chromatography/Mass Spectrometry (HPLC/MS). To evaluate ABS's anti-inflammatory efficacy, mouse macrophages underwent analysis using the Griess method. Induced differentiation of mouse fibroblasts was assessed through Oil Red O staining. In an obesity model with C57BL/6 N mice, ABS administration prompted measurements of glucose and insulin tolerance. Western blot analysis quantified lipolysis and anti-inflammatory protein expression. Nile red staining gauged body fat content in C. elegans post-ABS treatment. The mechanism of ABS action was elucidated through mRNA sequencing, further validated using RNA interference technology, and nematode mutants.
RESULTS: ABS showcased the ability to diminish Nitric Oxide (NO) production in inflammatory macrophages and shrink adipocyte lipid droplets. In mice experiments, ABS was effective in alleviating fat accumulation and affecting serum lipid metabolism in diabetic mice. It enhanced oral glucose tolerance and insulin tolerance while increasing lipolysis-associated protein expression. ABS notably reduced fat content in C. elegans. Mechanistically, ABS downregulated NOD-like receptor thermal protein domain associated protein 3 (NLRP3) and monoamine oxidase A (MAOA) expression while enhancing UGT, ilys-2, and ilys-3. Lipolysis emerged as a pivotal pathway for ABS in the therapeutic intervention of metabolic diseases.
CONCLUSIONS: Our investigation has revealed that ABS exert a role in combating metabolic diseases by enhancing the body's defense mechanisms. ABS activate the NLRP3-neurotransmitter-visceral adipose pathway in mice, thereby bolstering resistance and diminishing fat accumulation. In C. elegans, ABS downregulated the expression of MAOA, bolstered resistance, and augmented glucuronidase activity, consequently leading to a reduction in fat content.
According to recent meta-analyses, portion control tools represent an acceptable and potentially effective strategy to aid in weight loss. However, how well these tools work depends on their consistent use and a good integration with other lifestyle modification strategies around body weight control and overall health. The present pilot study was designed to evaluate the feasibility of a self-applied weight management intervention based on portion control and to identify factors influencing adherence. The sample will consist of 40 healthy volunteers with overweight/obesity who will engage in a pre-post intervetion study lasting six-months. The intervetion will include four components: (1) a portion control toolkit (serving spoon and oil dispenser); (2) a phsyical manual with instructions for using the tools, dietary and physical activity recommendations, and strategies to build habits and improve mental wellbeing; (3) a mobile app to motivate intervention engagement; and (4) biweekly short telephone support. Adherence to the intervention will be the primary outcome, assessed on a fortnightly basis as the change from baseline in dietary energy density and change in meal nutrient composition plus frequency of using the intervention components. Other measurements that will be taken at baseline, 3 and 6 months from baseline, will be: body composition, fasting biochemical parameters, inhibitory control (only baseline and 6 months), eating behaviour, portion size norms and intervention acceptance. After 3 months of taking part in the intervention, a subset of the sample will participate in a nominal group session aimed at identifying barriers to intervention adherence and strategies to overcome them. The study results will inform the design of a full-scale controlled trial featuring the most successful components.
Centralized networks have a small number of influential individuals, called "hubs," with connections to most other people. Centralized networks characterize situations in which most or all individuals are connected to, and seek advice from, a few well-connected "influencers." Each network is consisted of 40 individual participants. All network participants in this condition have very different baseline demographic characteristics, attitudes, or behavioral choices.
BACKGROUND: Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an option for treating EGPA.
METHODS: We conducted a multicenter, double-blind, phase 3, randomized, active-controlled noninferiority trial to evaluate the efficacy and safety of benralizumab as compared with mepolizumab. Adults with relapsing or refractory EGPA who were receiving standard care were randomly assigned in a 1:1 ratio to receive benralizumab (30 mg) or mepolizumab (300 mg) subcutaneously every 4 weeks for 52 weeks. The primary end point was remission at weeks 36 and 48 (prespecified noninferiority margin, -25 percentage points). Secondary end points included the accrued duration of remission, time to first relapse, oral glucocorticoid use, eosinophil count, and safety.
RESULTS: A total of 140 patients underwent randomization (70 assigned to each group). The adjusted percentage of patients with remission at weeks 36 and 48 was 59% in the benralizumab group and 56% in the mepolizumab group (difference, 3 percentage points; 95% confidence interval [CI], -13 to 18; P = 0.73 for superiority), showing noninferiority but not superiority of benralizumab to mepolizumab. The accrued duration of remission and the time to first relapse were similar in the two groups. Complete withdrawal of oral glucocorticoids during weeks 48 through 52 was achieved in 41% of the patients who received benralizumab and 26% of those who received mepolizumab. The mean (±SD) blood eosinophil count at baseline was 306.0±225.0 per microliter in the benralizumab group and 384.9±563.6 per microliter in the mepolizumab group, decreasing to 32.4±40.8 and 71.8±54.4 per microliter, respectively, at week 52. Adverse events were reported in 90% of the patients in the benralizumab group and 96% of those in the mepolizumab group; serious adverse events were reported in 6% and 13%, respectively.
CONCLUSIONS: Benralizumab was noninferior to mepolizumab for the induction of remission in patients with relapsing or refractory EGPA. (Funded by AstraZeneca; MANDARA ClinicalTrials.gov number, NCT04157348.).
The invention discloses a traditional Chinese medicine preparation for treating fracture and belongs to the field of traditional Chinese medicines. The traditional Chinese medicine preparation comprises the following effective constituents: pink reineckea herb, ophisaurus harti boulenger, herba lespedezae cuneatae, coelogyne cristata, osprey bone, picrasma quassioses (D.Don) benn, ficus virens, sida acuta, asplenium varians wall, pothos chinensis, hysimachia circaeoides heml, chamaenerion root, chonemorpha valvata chatt, marsdenia tenacissima, euphorbia heterophylla L. and tree falsespiraea bark. The preparation has the effects of reuniting bone, warming and activating meridian, strengthening tendons and bones and promoting blood circulation to remove blood stasis. By the adoption of the preparation, the activity and the number of osteoblasts can be improved, calcification of the bone matrix can be promoted, improvement of calluses can be accelerated, and local pain can be relieved. The traditional Chinese medicine preparation has more advantages than pure compounds and biological preparations and an obvious effect of promoting fracture healing, is a pure traditional Chinese medicine preparation and is quick in pain reliving, short in course of treatment, good in effect and low in medicine price. The total effective rate of treating fracture reaches 98%.